Ferring And Blackstone Launch Gene Therapy Company
Set Up To Market Nadofaragene Firadenovec For Bladder Cancer
The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.
You may also be interested in...
After more than three decades being associated with Novo Nordisk, Lars Rebien Sørensen has signed up to be chairman of Ferring, telling Scrip that the privately owned Swiss group's philosophy chimes with his own.
Takeda's divestment long has been rumored and would take it to its oft-stated target of selling around $10bn in assets to pay down debt associated with its $62bn purchase of Shire that closed in January 2019.
Private equity group Blackstone is reportedly near a deal to acquire Takeda's consumer health business in Japan for up to $2.8bn as the Japanese pharma firm continues to shed non-core assets.